Document Detail


In vitro evaluation of bevacizumab toxicity on a retinal ganglion cell line.
MedLine Citation:
PMID:  19563375     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: The effects of bevacizumab on cell viability and proliferation in a commonly used retinal ganglion cell line, RGC-5, were examined.
METHODS: RGC-5 cells were exposed to 0.1 mg/ml, 1 mg/ml and 2 mg/ml of commercially available bevacizumab in vitro. To examine the specificity of effects, cells were also cultured with increasing and comparable concentrations of proteins (increasing the concentration of proteins in the culture media by 0.1 mg/ml, 1 mg/ml and 2 mg/ml by using additional fetal bovine serum [FBS] and bovine serum albumin [BSA]). Cell proliferation was assessed using a WST-1 kit, crystal violet staining and bromodeoxyuridine (BrdU) incorporation. Cytotoxic effects were assessed by quantifying cell numbers in proliferation-deficient RGC-5 following exposure to bevacizumab using the WST-1 kit, microscopic examination of cells stained with propidium iodide (PI) cells and flow cytometry for differential staining with PI.
RESULTS: Bevacizumab was not toxic to RGC-5 cells in the tested concentrations. It had a stimulatory effect on cell proliferation. A stimulatory effect on proliferation was also noted when equivalent amounts of proteins from FBS or BSA were used, which suggests that bevacizumab may stimulate proliferation non-specifically by increasing the protein contents of the cell growth environment.
CONCLUSIONS: Results suggest that intravitreal injection of bevacizumab could alter the internal milieu of the eye by increasing protein concentrations to elicit functional responses in retinotypic cells. This may be especially relevant for cells outwith the control of vascular endothelial growth factor.
Authors:
Rajesh K Sharma; Kakarla V Chalam
Related Documents :
16239285 - Enhanced pathogenicity of candida albicans pre-treated with subinhibitory concentration...
6572725 - Prostaglandin biosynthesis by a human macrophage-like cell line, u937.
20668365 - Transforming growth factor beta1 alters calcium mobilizing properties and endogenous at...
7214335 - Inhibitory effects of selenium on the growth of l1210 leukemic cells.
11538275 - Light-stimulated cell expansion in bean (phaseolus vulgaris l.) leaves. i. growth can o...
701365 - Direct measurement of species-specific cohesion in cellular slime molds.
Publication Detail:
Type:  Journal Article     Date:  2009-06-26
Journal Detail:
Title:  Acta ophthalmologica     Volume:  87     ISSN:  1755-3768     ISO Abbreviation:  Acta Ophthalmol     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-09-01     Completed Date:  2009-11-10     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  101468102     Medline TA:  Acta Ophthalmol     Country:  England    
Other Details:
Languages:  eng     Pagination:  618-22     Citation Subset:  IM    
Affiliation:
Department of Ophthalmology, University of Florida, College of Medicine, Jacksonville, Florida 32209, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiogenesis Inhibitors / toxicity*
Animals
Antibodies, Monoclonal / toxicity*
Antibodies, Monoclonal, Humanized
Bromodeoxyuridine / metabolism
Cattle / blood,  embryology
Cell Line
Cell Proliferation / drug effects
Cell Survival / drug effects
Dose-Response Relationship, Drug
Fetal Blood
Osmolar Concentration
Rats
Retinal Ganglion Cells / drug effects*,  metabolism,  physiology
Serum Albumin, Bovine / pharmacology
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Serum Albumin, Bovine; 2S9ZZM9Q9V/bevacizumab; 59-14-3/Bromodeoxyuridine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical features and follow-up results of pulsating polypoidal choroidal vasculopathy treated with ...
Next Document:  Review article: Early detection of chronic kidney disease in Australia: Which way to go?